Mycophenolate Mofetil
It is hydroloysed to MPA which inhibits T & B Iymphocyte proliferation and antibody formation by B lymphocytes. It may inhibit recruitment of leucocytes and graft rejection.Prophylaxis of organ rejection in renal and cardiac transplant cases.
Hypersensitivity to the drug or any component of drug product; sensitivity to polysorbate 80 (tween).
Monitoring of CBC should be done, administer cautiously in patients with active serious GI disease. Instruct patients with increased risk of skin cancer to limit sunlight exposure and use sunscreen. If neutropenia develops during course of treatment, interrupt or reduce the dose and manage patient appropriately.
Diarrhoea, leukopenia, sepsis, vomiting, predisposition to certain infections e.g. CMV viraemia, TB, possible development of lymphoma, GI haemorrhage.
Avoid simultaneous administration with antacid, cholestyramine or agents which inhibit enterohepatic circulation. Probenecid increases plasma levels of mycophenolate may increase phenytoin and theophylline levels by decreasing their protein binding. Avoid concomitant use of azathioprine.
